IKT · NASDAQ
Average $6.12 (+257.9% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| Chardan Capital | Oct 13, 2026 | Initiates | Neutral |
| Oppenheimer | Jun 10, 2026 | Initiates | Outperform |
| Ladenburg Thalmann | Mar 4, 2026 | Initiates | Buy |
| B of A Securities | Jan 21, 2026 | Initiates | Buy |
| HC Wainwright & Co. | Dec 26, 2025 | Initiates | Buy |
| Freedom Broker | Dec 17, 2025 | Initiates | Buy |
| Cantor Fitzgerald | Dec 11, 2025 | Initiates | Overweight |
Updated Jun 12, 2026
Inhibikase Therapeutics is expected to see strong growth and success with the launch of their new drug IKT-001 in 2030, with a potential revenue of $1.4B. The company's adaptive Phase 3 trial design sets it apart from competitors and has the potential to shorten development time by 3 years. With promising results and a unique mechanism of action, IKT-001 is seen as a valuable option for future success and has received an Outperform rating.
Inhibikase Therapeutics is a clinical-stage pharmaceutical company with a focus on developing therapeutics for cardiopulmonary diseases, mainly Pulmonary Arterial Hypertension (PAH), and modifying the course of these diseases. Despite a promising portfolio of protein kinase inhibitors and recent financing efforts, the company has limited current market value, putting significant pressure on its upcoming Phase 3 clinical trial for its lead candidate, IKT-001, to demonstrate significant improvement and tolerability in PAH patients in order to justify its valuation. However, there are potential risks and challenges to the company's success, including competition and market access issues, potential delays in clinical trial initiation and enrollment, and the possibility of generic erosion in the long term.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
